Most Common Adverse Events Key Observations: Gastrointestinal adverse events are dose-dependent and most pronounced during dose escalation Symptoms typically peak within the first 4-8 weeks and diminish with continued treatment as tolerance develops Slow titration (4-week intervals) significantly reduces the incidence and severity of GI events Most adverse events classified as mild to moderate in severity [9] Discontinuation Rates 7.3% Placebo discontinuation rate [9] 15.8% Cagrilintide 2.4 mg (optimal dose) [9] 24.5% Cagrilintide 4.5 mg (high dose) [9] The majority of discontinuations due to adverse events occurred during the titration phase, with GI symptoms (nausea, vomiting) being the primary reasons
10.1039/d1fo01729b 326 ZhaZ.LvY.TangH.LiT.MiaoY.ChengJ.et al (2020)
Implication of processed pseudogenes derived from heme oxygenase-2 gene
At our clinic in Doral, we see patients from across Miami, Hialeah, Kendall, and Westchester who made the same journey from supplement to supervised protocol
Parkinsons, Alzheimers and other researchers are embedding nanoparticles of drugs in a substance called chitosan (a biodegradable, biocompatible polymer) which can adhere to mucous membranes in the nose and release much more of the drug much deeper into the brain than aerosolized preparations do
This combination of mechanistic plausibility and clinical evidence has demonstrated the potential for GLP-1RAs as a possible therapeutic strategy for improving cardiovascular prognosis
